Unique ID issued by UMIN | UMIN000051660 |
---|---|
Receipt number | R000058947 |
Scientific Title | Investigation for biomarkers for "silent progression" in neuromyelitis optica spectrum disorders and multiple sclerosis |
Date of disclosure of the study information | 2023/08/01 |
Last modified on | 2024/04/18 19:48:10 |
Investigation for biomarkers for "silent progression" in neuromyelitis optica spectrum disorders and multiple sclerosis
Observational Study on "Silent Progression" in NMOSD/MS
Investigation for biomarkers for "silent progression" in neuromyelitis optica spectrum disorders and multiple sclerosis
Observational Study on "Silent Progression" in NMOSD/MS
Japan |
neuromyelitis spectrum disorder, multiple sclerosis
Neurology |
Others
NO
This study aimed to assess whether indicators of the glymphatic system contribute to the progression of neuromyelitis spectrum disorder and multiple sclerosis independent of relapses.
Others
This study aimed to assess whether the indicators of the glymphatic system differ for each therapeutic agent in neuromyelitis spectrum disorder.
diffusion tensor image analysis along the perivascular space (DTI ALPS) index
Observational
18 | years-old | <= |
Not applicable |
Male and Female
1 Patients diagnosed with neuromyelitis optica spectrum disorder or multiple sclerosis.
2 Patients fulfilling the 2015 International Panel NMOSD diagnostic criteria for neuromyelitis optica spectrum disorder.
3 Patients fulfilling the 2017 McDonald diagnostic criteria for multiple sclerosis.
4 Adult patients aged 18 years or older when obtaining consent, regardless of gender.
5 Patients from whom consent for participation in this study is obtained in writing by the individual themselves.
1 Patients with the following complications:
Cirrhosis of the liver
Acute fulminant hepatitis
Congenital amino acid metabolic disorders
Severe malnutrition requiring treatment
2 Patients who lack the capacity or willingness to follow instructions for tests, such as fasting blood sampling.
3 Patients deemed unsuitable for participation in this study by the principal investigator or research collaborators.
180
1st name | Jin |
Middle name | |
Last name | Nakahara |
Keio University School of Medicine
Department of Neurology
160-0016
35 Shinanomachi, Shinjuku-ku, Tokyo, Japan
03-3353-1211
nakahara@a6.keio.jp
1st name | Haruhiko |
Middle name | |
Last name | Motegi |
Keio University School of Medicine
Department of Neurology
160-0016
35 Shinanomachi, Shinjuku-ku, Tokyo, Japan
03-3353-1211
nakahara@a6.keio.jp
Keio University School of Medicine
CHUGAI PHARMACEUTICAL CO., LTD.
Profit organization
Keio University School of Medicine Ethics Committee
35 Shinanomachi, Shinjuku-ku, Tokyo, Japan
03-5363-3503
med-rinri-jimu@adst.keio.ac.jp
NO
2023 | Year | 08 | Month | 01 | Day |
Unpublished
Enrolling by invitation
2023 | Year | 07 | Month | 20 | Day |
2023 | Year | 12 | Month | 26 | Day |
2024 | Year | 04 | Month | 12 | Day |
2026 | Year | 03 | Month | 31 | Day |
None in particular
2023 | Year | 07 | Month | 20 | Day |
2024 | Year | 04 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000058947
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |